Obinutuzumab plus CHOP is effective and has a tolerable safety profile in previously untreated, advanced diffuse large B-cell lymphoma: the phase II GATHER study

This study investigated the safety and efficacy of obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (G-CHOP) in patients with advanced diffuse large B-cell lymphoma (DLBCL) and explored the impact of cell-of-origin (COO) on patient outcomes. Patients (N = 100) received ob...

詳細記述

保存先:
書誌詳細
出版年:Leuk Lymphoma
主要な著者: Sharman, Jeff P., Forero-Torres, Andres, Costa, Luciano J., Flinn, Ian W., Inhorn, Lowell, Kelly, Kevin, Bessudo, Alberto, Fayad, Luis E., Kaminski, Mark S., Evens, Andrew M., Flowers, Christopher R., Sahin, Deniz, Mundt, Kirsten E., Sandmann, Thomas, Fingerle-Rowson, Günter, Vignal, Charlotte, Mobasher, Mehrdad, Zelenetz, Andrew D.
フォーマット: Artigo
言語:Inglês
出版事項: 2018
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6445782/
https://ncbi.nlm.nih.gov/pubmed/30277102
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2018.1515940
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料